Dan O'Day (AP Images)
A name emerges out of the Gilead M&A rumor mill, and it’s a cancer biotech
After months of questions and speculation about when and if Gilead will make a major acquisition, a name has emerged.
The California-based drugmaker has approached Forty Seven Inc, a cancer biotech, with a takeover offer, Bloomberg News reports. With Forty Seven’s market cap at $2.3 billion, an acquisition would likely be Gilead’s largest since they acquired Kite Pharma for $11.9 billion in 2017.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
